Skip to main content
NTRA
NASDAQ Industrial Applications And Services

Natera Q3 Revenue Jumps 34% to $794M; Net Loss Narrows to $59.9M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$293.974
Mkt Cap
$52.434B
52W Low
$181
52W High
$437.408
52W Position info
62% above low
Off High info
33% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

NTRA sits 62% above its 52-week low of $181 on elevated volume (2.0× avg).

Summary

Natera reported Q3 2026 revenue of $794.0 million, up 34.1%, with the net loss narrowing to $59.9 million and $1.097 billion in cash. The 10-Q also discloses a CEO change effective November 5, 2026 and a $30.0 million acquisition of a strategic partner.


Key Events · Earnings and Guidance · NTRA

  • Q3 Revenue Up 34.1% to $794M

    Total revenues were $793.981 million versus $592.183 million a year ago, driven by higher test volumes and a higher average selling price.

  • Net Loss Narrows to $59.9M

    Q3 2026 net loss was $59.9 million versus $87.5 million a year ago; nine-month net loss was $212.0 million versus $255.4 million.

  • Cash of $1.097B, $80.3M Drawn

    Cash, cash equivalents and restricted cash totaled $1.097 billion at September 30, 2026, with $80.3 million outstanding on the UBS credit line and $20.0 million remaining available.

  • CEO Transition Effective November 5

    Steve Chapman resigned and Solomon Moshkevich was appointed CEO and President effective November 5, 2026; Chapman receives a $1,000,000 lump-sum transition payment and a $1,500,000 target 2026 bonus.


Analysis · NTRA · Industrial Applications And Services

Revenue growth of 34.1% with gross margin holding at 64.7% shows the Signatera-led oncology ramp is scaling without margin erosion, and the net loss narrowed to $59.9 million from $87.5 million a year ago. The balance sheet remains strong with $1.097 billion in cash against only $80.3 million drawn on the UBS credit line, so there is no near-term financing pressure. Two subsequent events matter for the thesis: a new CEO (Solomon Moshkevich, effective November 5, 2026) and a small $30.0 million acquisition of a strategic partner on November 2, 2026.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, NTRA was trading at $293.97 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $52.4B. The 52-week trading range was $181.00 to $437.41. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

NTRA - Latest Insights

NTRA
Nov 06, 2026, 11:25 AM EST
Source: Benzinga
Importance Score:
7
Price at Filing: $316.02
Real-time Price: $285.54 info
Change: -$30.48 (-10%) info
Market Cap: $42.04B info
NTRA
Nov 05, 2026, 4:06 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $366.75
Real-time Price: $285.54 info
Change: -$81.21 (-22%) info
Market Cap: $42.04B info
NTRA
Nov 05, 2026, 4:05 PM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $363.76
Real-time Price: $285.54 info
Change: -$78.22 (-22%) info
Market Cap: $42.04B info
NTRA
Nov 03, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $380.77
Real-time Price: $285.54 info
Change: -$95.23 (-25%) info
Market Cap: $42.04B info
NTRA
Oct 09, 2026, 8:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $391.54
Real-time Price: $285.54 info
Change: -$106.00 (-27%) info
Market Cap: $42.04B info